Akebia Therapeutics Inc expected to post a loss of 2 cents a share - Earnings Preview

Akebia Therapeutics

23/08/2023 13:33

* Akebia Therapeutics Inc  AKBA.OQ   AKBA.O  is expected
to show a
fall in quarterly revenue when it reports  results on August
25. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 53.4% decrease in revenue to $59.1 million from $126.76
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Akebia Therapeutics
Inc
is for a loss of 2 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akebia
Therapeutics Inc is $3​, above​ its last closing price of $1.26.
​​​

This summary was machine generated August 23 at 12:33 GMT.  All
figures in US dollars  unless otherwise stated